Strategic partnerships Collaborate with established medical device and imaging partners (e.g., Ricoh 3D for Healthcare, Mayo Clinic) to co-develop AI-driven breast cancer decision support and integrate TumorSight into clinical workflows, unlocking broader adoption and credibility.

Clinical validation Leverage multi-institutional study data and upcoming presentations at major conferences (MBCC, ASBrS) to secure speaking engagements, expand speaking opportunities, and convert clinical traction into payer-ready evidence for reimbursement discussions.

Executive leadership Engage with the current leadership trajectory and upcoming AI/tech leadership hires to align value propositions around AI-driven precision medicine, targeting enterprise customers and hospital networks seeking advanced decision support solutions.

NGO and KOL outreach Target oncology researchers, breast surgeons, and radiology thought leaders through pilot programs and co-authored studies to build reference sites, accelerating adoption among mid-to-large health systems.

Market expansion Position Spatial Biophysics offerings to expand beyond breast cancer into other tumor types and imaging modalities, using the company’s AI and modeling capabilities to attract new customers in biopharma and academic centers seeking personalized therapy planning.